Viral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strategy to control such viral infections, with the successful and recently accelerated development of different types of vaccines, thanks to the advanced biotechnological techniques involved in the upstream and downstream processing of these products. However, there is still much work to be done for the improvement of efficacy and safety when it comes to the choice of delivery systems, formulations, dosage form and route of administration, which are not only crucial for immunisation effectiveness, but also for vaccine stability, dose frequency, patient convenience and logistics for mass immunisation. In this review, we discuss the main vaccine delivery systems and associated challenges, as well as the recent success in developing nanomaterials-based and advanced delivery systems to tackle these challenges. Manufacturing and regulatory requirements for the development of these systems for successful clinical and marketing authorisation were also considered. Here, we comprehensively review nanovaccines from development to clinical application, which will be relevant to vaccine developers, regulators, and clinicians.
Multicomponent peptide nanostructures offer a powerful platform for designing functional materials, yet controlling their co‐assembly remains a key challenge. Here, we harness electrostatic molecular recognition to drive the selective co‐assembly of five amphiphilic ionic peptide binary mixtures (M 1 –M 5 ). Our results revealed that charge distribution governs β‐sheet strand alignment (parallel vs. antiparallel), assembly kinetics, and hydrogel viscoelasticity. Mixing stoichiometry and pH significantly influences co‐assembly behavior, nanofiber morphology, and network structure (self‐sorted vs. hetero‐aggregated). At pH 7, equimolar mixtures undergo nucleation‐driven co‐assembly into hetero‐aggregates, immediately forming well‐defined nanofibers, while non‐equimolar ratios yield altered morphologies. At a slightly acidic pH of 5–7, both E and K side chains are charged, enabling complementary ionic interactions that promote co‐assembly and gelation. Outside this pH range, co‐assembly is impaired. Notably, M 1 forms β‐sheets and hydrogels at acidic pH (≤4) via independent self‐assembly of its components, suggesting self‐sorted fibers. Overall, we demonstrate that tuning charge complementarity, ionization state, and stoichiometry enables precise control over the molecular, nanoscale, and mechanical properties of multicomponent peptide assemblies, providing a framework for the rational design of advanced peptide‐based materials.
Organ‐on‐chip (OoC) technologies and long‐acting therapeutics (LATs) are two rapidly advancing fields that have not yet been meaningfully integrated. This review argues that their convergence represents a significant and timely opportunity. LAT development is constrained by a preclinical toolbox that fails to capture the coupled, tissue‐dependent processes, depot formation, sustained release, interstitial transport, host response, and local clearance that govern long‐acting performance in vivo. OoC platforms can reproduce the physiological microenvironments in which these processes unfold, including barrier structure, controlled perfusion, mechanical cues, and multicellular organization, under reproducible in vitro conditions. This review first maps the scientific and translational challenges of LAT development and the mechanistic requirements any preclinical platform must address. It then shows how the core design principles of OoC technology enable tissue‐mimicking platforms that reproduce the microenvironments of the main LAT administration routes. Finally, it brings the two fields together, mapping each LAT requirement directly onto a specific OoC capability, showing that the challenges of scale and long‐term culture stability are tractable through defined mitigation strategies, and setting out how the standardization and regulatory alignment now underway can position OoC platforms as credible decision‐support tools that complement, rather than replace, existing in vitro release models.